Skip to content

Lifecore Biomedical, Inc. LFCR Debt Maturity - 2027

Debt Maturity - 2027 at other companies

ADMA Biologics logo
ADMA BiologicsADMA
$0

Other financials

Income statement

See full
Revenue$23.2M-36.4%
Gross profit$4.5M-68.1%
Operating income-$4.7M
Net income-$15.0M-1,206%
EPS (diluted)-$0.43-1,333%

Balance sheet

See full
Cash & equivalents$20.8M+152%
Total debt$156.9M+1,310%
Total equity-$28.4M-2,229%
Total assets$225.5M-5.8%

Cash flow

See full
Operating cash flow$4.7M
CapEx$1.1M-46.7%
Free cash flow$3.6M

Valuation

See full
Market cap$196.92M-35.4%
Enterprise value$333.06M+8.3%
P/S1.6×+0.5×

Profitability

See full
Gross margin31.3%-1.4pp
Operating margin-14.5%-2.2pp
Net margin-30%
FCF margin-36.4%

Returns & leverage

See full
Return on equity-612.1%
Debt / equity8.3×-1.5×
Current ratio3.8×+0.9×

Where this comes from

Reported directly by Lifecore Biomedical, Inc. in its filing.

Tagged under the XBRL concept us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree.

The official record: Lifecore Biomedical, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lifecore Biomedical, Inc.'s debt maturity - 2027.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lifecore Biomedical, Inc.'s debt maturity - 2027?
Lifecore Biomedical, Inc. (LFCR) reported debt maturity - 2027 of $189.68M in Q1 2026.
What does debt maturity - 2027 mean?
The specific principal amount of debt obligations scheduled to mature in the year 2027. This metric is essential for assessing the company's liquidity risk and refinancing requirements in a specific future period. It helps investors understand the timing of potential cash outflows related to debt repayment.